latest news from cognivia
Multiple gene alterations and insertions to CA3 hippocampal neurones demonstrated in vivo with 99.8% success rate.
Study shows second-generation Mnemosyne (MNS) provides significantly greater event recall improvement than other market drugs.
Cognivia acquires 51% stake in Agilon AI.
Cognivia - Board and Directorate changes.
New drug application submitted to Perplex City authorities for in situ production of CNS boosters.
Online science exhibit wins Perplex City Understanding award - exhibit recognised for helping students learn about medical imaging and diagnostics.
Cognivia grants a voluntary licence for generic production and sale of second-generation Ceretin.
New data shows new Halcyon delivers rapid onset of action and lasting anxiolytic effect with reduced side-effects.
Cognivia responds to Academy Cognitive Enhancement Advisory Committee recommendations on use of analytical and systemising enhancers in mission-critical situations.
264 winner of the Academy Games joins Cognivia's 'Understanding the Senescence Problem' team.
New survey provides insights into unique relationship between teachers, students and cognitive psychologists.
Keynote presentation by Cognivia CEO at the Fourth Cerebral Prostheses Conference.
Cognivia updates publicly accessible database on clinical-trial information.
Cognivia ranked first in Perplex City 100 list.
Full archives of Cognivia news are currently not accessible.